---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-26-066087"
form_type: "8-K"
ticker: "CSBR"
cik: "0000771856"
company_name: "CHAMPIONS ONCOLOGY, INC."
filed_at: "2026-10-16T16:15:14+00:00"
generated_at: "2026-10-16T16:16:07.210315+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.22
calibrated_materiality_score: 0.15
confidence: "high"
source: SEC EDGAR
---

# Champions Oncology holders re-elect 7 directors, ratify EisnerAmper, approve 2026 Equity Incentive Plan

## Summary
- All seven director nominees elected at the Oct 14, 2026 annual meeting; Brian Alexander (8,241,264 for) and Scott Tobin (8,230,372) drew the least opposition.
- David Sidransky received 7,154,225 for vs 1,088,685 withheld, the largest dissent; Robert Brainin got 7,904,120 for / 338,790 withheld.
- EisnerAmper LLP ratified as independent auditor for fiscal year ending April 30, 2027, by 8,702,771 for to 1,845 against.
- 2026 Equity Incentive Plan approved 6,401,638 for / 754,480 against (~10.5% opposition) with 1,086,792 abstentions.
- Say-on-pay approved 7,130,832 for vs 25,242 against; holders favored annual advisory votes (7,198,608 for 1 year), and the company will hold them yearly.

## SEC filing metadata
- accession: 0001628280-26-066087
- form_type: 8-K
- ticker: CSBR
- cik: 0000771856
- company_name: CHAMPIONS ONCOLOGY, INC.
- filed_at: 2026-10-16T16:15:14+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.22
- calibrated_materiality_score: 0.15
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/771856/000162828026066087/0001628280-26-066087-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/771856/000162828026066087/csbr-20261014.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-26-066087
- JSON: https://secwatch.observer/filing/0001628280-26-066087.json
- Plain text: https://secwatch.observer/filing/0001628280-26-066087.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.